{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:20:19Z","timestamp":1793701219809,"version":"4.5.1"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T00:00:00Z","timestamp":1403049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    We report our experience with 129 cases of double hit lymphoma (\n                    <jats:styled-content style=\"fixed-case\">DHL<\/jats:styled-content>\n                    ), defined as B\u2010cell lymphoma with translocations and\/or extra signals involving\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">MYC<\/jats:styled-content>\n                    <\/jats:italic>\n                    plus\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>\n                      2\n                    <\/jats:italic>\n                    and\/or\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>\n                      6\n                    <\/jats:italic>\n                    . All cases were reviewed for histopathological classification. Median age was 62\u00a0years (range, 18\u201385), 84% of patients had advanced\u2010stage disease, and 87% had an International Prognostic Index score \u22652. Fourteen patients (11%) had a history of low\u2010grade follicular lymphoma.\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">MYC<\/jats:styled-content>\n                    <\/jats:italic>\n                    translocation was present in 81%, and extra signals of\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">MYC<\/jats:styled-content>\n                    <\/jats:italic>\n                    in 25% of patients.\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">IGH<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>\n                      2\n                    <\/jats:italic>\n                    translocation was present in 84% and extra signals of\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>\n                      2\n                    <\/jats:italic>\n                    in 12% of patients. Two\u2010year event\u2010free survival (\n                    <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>\n                    ) rates in all patients and patients who received R\u2010\n                    <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\n                    (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), R\u2010\n                    <jats:styled-content style=\"fixed-case\">EPOCH<\/jats:styled-content>\n                    (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and R\u2010Hyper\n                    <jats:styled-content style=\"fixed-case\">CVAD<\/jats:styled-content>\n                    \/\n                    <jats:styled-content style=\"fixed-case\">MA<\/jats:styled-content>\n                    (rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate) were 33%, 25%, 67% and 32%, respectively. In patients achieving complete response with initial therapy (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a071), 2\u2010year\n                    <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>\n                    rates in patients who did (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a023) or did not (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a048) receive frontline stem cell transplantation were 68% and 53%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b7155). The cumulative incidence of central nervous system involvement was 13% at 3\u00a0years. Multivariate analysis identified performance status \u22652 and bone marrow involvement as independent adverse prognostic factors for\n                    <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>\n                    and\n                    <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>\n                    . Further research is needed to identify predictive and\/or targetable biological markers and novel therapeutic approaches for\n                    <jats:styled-content style=\"fixed-case\">DHL<\/jats:styled-content>\n                    patients.\n                  <\/jats:p>","DOI":"10.1111\/bjh.12982","type":"journal-article","created":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T10:05:39Z","timestamp":1403085939000},"page":"891-901","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":339,"title":["Double hit lymphoma: the\n                    <scp>MD A<\/scp>\n                    nderson\n                    <scp>C<\/scp>\n                    ancer\n                    <scp>C<\/scp>\n                    enter clinical experience"],"prefix":"10.1111","volume":"166","author":[{"given":"Yasuhiro","family":"Oki","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Noorani","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea C.","family":"Pinnix","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard J.","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Turturro","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-297879"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404529"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/2.1.85"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5800"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212191"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800500"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11305"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.147"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1558"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.344"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12585"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181cd3aeb"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301077"},{"key":"e_1_2_8_23_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.005355"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1391"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12982","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:05:13Z","timestamp":1696273513000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,18]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/bjh.12982"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12982","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718457660.793521340","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,18]]},"assertion":[{"value":"2014-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}